- /
- Supported exchanges
- / TW
- / 2457.TW
Phihong Technology Co Ltd (2457 TW) stock market data APIs
Phihong Technology Co Ltd Financial Data Overview
Phihong Technology Co., Ltd. operates as a power supply company in Taiwan. The company offers adapters, such as desktop adapter, fixed plug wall adapter, and interchangeable plug wall adapter; power-over-ethernet solutions, including PoE injector and splitter, media converter, and PoE to USB C; and medical open frame and medical adapter. It also provides battery charger solutions; open frame and internal PSU; and EV chargers. The company was formerly known as Phihong Enterprise Co., Ltd. and changed its name to Phihong Technology Co., Ltd. in June 2003. Phihong Technology Co., Ltd. was founded in 1972 and is based in Taoyuan City, Taiwan.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Phihong Technology Co Ltd (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Phihong Technology Co Ltd data using free add-ons & libraries
Get Phihong Technology Co Ltd Fundamental Data
Phihong Technology Co Ltd Fundamental data includes:
- Net Revenue: 10 629 M
- EBITDA: -252 570 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-08-11
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Phihong Technology Co Ltd News
New
Histogen and Amerimmune Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients
Emricasan Found to be Safe and Well Tolerated with No Serious Adverse Events Patients Completing Treatment with Emricasan had a Complete Resolution of the Symptoms Most Commonly Associated in Mild CO...
Histogen and Amerimmune Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients
Emricasan Found to be Safe and Well Tolerated with No Serious Adverse Events Patients Completing Treatment with Emricasan had a Complete Resolution of the Symptoms Most Commonly Associated in Mild CO...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.